Volume 28, Number 11—November 2022
Research
Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents
Table 2
Result of booster vaccination among immunocompromised persons and LTCF residents in COVID-19 vaccine effectiveness study, South Korea, February–May 2022*
Characteristics | Population |
All infection, no. (%) |
Critical infection, no. (%) |
Death, no. (%) |
|||||
---|---|---|---|---|---|---|---|---|---|
No. (%) |
Person-days | ||||||||
Total |
972,449 |
44,372,598 |
313,388 |
2,951 |
2,441 |
||||
1st booster | 736,439 (75.7) | 39,175,439 | 268,278 (85.6) | 2,609 (88.4) | 2,148 (88.0) | ||||
2nd booster |
236,010 (24.3) |
5,197,160 |
45,110 (14.4) |
342 (11.6) |
293 (12.0) |
||||
Sex | |||||||||
F | 583,013 (60.0) | 26,146,920 | 206,478 (65.9) | 1,236 (41.9) | 1,474 (60.4) | ||||
M |
389,436 (40.0) |
18,225,678 |
106,910 (34.1) |
1,715 (58.1) |
967 (39.6) |
||||
Age group, y | |||||||||
18–39 | 41,821 (4.3) | 1,806,401 | 17,391 (5.5) | 4 (0.1) | 1 (0.0) | ||||
40–59 | 229,379 (23.6) | 10,150,253 | 86,230 (27.5) | 97 (3.3) | 62 (2.5) | ||||
60–74 | 429,816 (44.2) | 20,123,745 | 117,935 (37.6) | 511 (17.3) | 335 (13.7) | ||||
>75 |
271,433 (27.9) |
12,292,199 |
91,832 (29.3) |
2,339 (79.3) |
2,043 (83.7) |
||||
Location | |||||||||
Metropolitan area | 440,460 (45.3) | 20,137,934 | 137,973 (44.0) | 1,328 (45.0) | 1,012 (41.5) | ||||
Nonmetropolitan area |
531,989 (54.7) |
24,234,664 |
175,415 (56.0) |
1,623 (55.0) |
1,429 (58.5) |
||||
Risk factors | |||||||||
Immunocompromised | 574,693 (59.1) | 27,697,324 | 124,950 (39.9) | 531 (18.0) | 339 (13.9) | ||||
LTCF residents | 397,756 (40.9) |
16,675,274 | 188,438 (60.1) |
2,420 (82.0) |
2,102 (86.1) |
*LTCF, long-term care facility.
1These authors contributed equally to this article.